To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)

Exclusion Criteria

• •Patients with a significant respiratory disease other than COPD. A significant disease is defined as a disease which, in the opinion of the investigator
• •Patients with a medical disorder, condition or history of such that would impair the patients ability to participate or complete this study in the opinion of the investigator, patients who have mental disorder which is inappropriate to communal living in a participation in a clinical study, who have no ability to give informed consent, or who have physical disability
• •Patients with a history of CF
• •Patients with clinically evident bronchiectasis
• •Patients with a history of asthma
• •Patients who have undergone thoracotomy with pulmonary resection
• •Patients with relevant conspicuous findings in medical history and pre-study examination not related to the underlying disease